BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Short Bowel Syndrome readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Short Bowel Syndrome\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06973304-9608@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:teduglutide (Gattex): Phase 3 readout est. (NCT06973304)
DESCRIPTION:teduglutide (Gattex)\, phase 3\, Short Bowel Syndrome.\nStudy: 
 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome\nEstima
 ted primary completion: 10 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teduglutide-gattex#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06973304
URL:https://assetmemo.bio/drug/teduglutide-gattex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904872-1030@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Mytesi (Crofelemer): Phase 2 readout est. (NCT06904872)
DESCRIPTION:Mytesi (Crofelemer)\, phase 2\, Short Bowel Syndrome.\nStudy: S
 afety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndro
 me and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)\nEsti
 mated primary completion: March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/crofelemer#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06904872
URL:https://assetmemo.bio/drug/crofelemer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05018286-10886@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:apraglutide: Phase 3 readout est. (NCT05018286)
DESCRIPTION:apraglutide\, phase 3\, Short Bowel Syndrome.\nStudy: Open-labe
 l Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short
  Bowel Syndrome.\nEstimated primary completion: 30 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/apraglutide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05018286
URL:https://assetmemo.bio/drug/apraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742735-10886@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:apraglutide: Phase 3 readout est. (NCT07742735)
DESCRIPTION:apraglutide\, phase 3\, Short Bowel Syndrome.\nStudy: A Study t
 o Investigate the Efficacy and Safety of Apraglutide Compared With Placebo
  in Adult Participants With Short Bowel Syndrome Associated With Intestina
 l Failure (SBS-IF)\nEstimated primary completion: October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/apraglutide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07742735
URL:https://assetmemo.bio/drug/apraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
